The Latest in Community Translations

The Journal of Community and Supportive Oncology

Paradigm-changing osimertinib approval in front-line for advanced NSCLC

December 6, 2018

Lung Cancer

The Journal of Community and Supportive Oncology

BRAF-MEK inhibitor combo approved for adjuvant melanoma therapy

December 6, 2018

Melanoma

The Journal of Community and Supportive Oncology

Venetoclax approved to treat CLL patients regardless of genotype

October 28, 2018

Lymphoma & Plasma Cell Disorders

The Journal of Community and Supportive Oncology

Nivolumab and ipilimumab combination promises new standard of care for advanced RCC

October 28, 2018

Genitourinary Cancer

The Journal of Community and Supportive Oncology

Neratinib extends adjuvant treatment of patients with HER2-positive breast cancer

August 26, 2018

Breast Cancer

The Journal of Community and Supportive Oncology

More biosimilars reach the market in efforts to improve access and cut costs

August 26, 2018

Patient & Survivor Care

The Journal of Community and Supportive Oncology

First CAR T-cell therapy approvals bolster booming immunotherapy market

August 15, 2018

The Journal of Community and Supportive Oncology

Lenalidomide becomes standard of care for multiple myeloma in the maintenance setting

August 2, 2018

Lymphoma & Plasma Cell Disorders

The Journal of Community and Supportive Oncology

Expanded approval for daratumumab in multiple myeloma

August 2, 2018

Lymphoma & Plasma Cell Disorders

The Journal of Community and Supportive Oncology

Bevacizumab-awwb becomes first biosimilar approved for cancer treatment

April 29, 2018

The Journal of Community and Supportive Oncology

Trastuzumab-dkst approval adds to the biosimilar cancer drug market

April 29, 2018

The Journal of Community and Supportive Oncology

Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer

February 19, 2018

Breast Cancer

The Journal of Community and Supportive Oncology

Checkpoint inhibitors forge new treatment paradigm for metastatic bladder cancer

February 18, 2018

Genitourinary Cancer

The Journal of Community and Supportive Oncology

Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval

December 15, 2017

The Journal of Community and Supportive Oncology

Brigatinib approval yields additional treatment options for crizotinib-resistant, ALK-positive NSCLC patients

December 15, 2017

Lung Cancer